The Daruma Institute for AI in Pharmaceutical Research has opened its doors. It is mainly devoted to artificial intelligence platforms for molecular therapeutics, with emphasis on therapeutic steering of cancer evolution. It is currently headed by Ariel Fernández.
Ariel Fernández (born Ariel Fernández Stigliano) is an Argentinian-American physical chemist and mathematician. He obtained a Ph. D. degree in Chemical Physics from Yale University and held the Karl F. Hasselmann Endowed Chair Professorship in Bioengineering at Rice University. He is currently involved in research and entrepreneurial activities at various consultancy firms. Ariel Fernández authored five books on translational medicine and biophysics, and published over 400 papers in professional journals. He also holds two patents in the field of biotechnology.
Publications related to the mission of the Institute:
Ariel Fernández and L. Ridgway Scott: “Advanced modeling reconciles counterintuitive decisions in lead optimization”. Trends in Biotechnology, CELL Press 35, 490-497 (2017).
Ariel Fernández: “Making targeted therapy compatible with checkpoint immunotherapy”. Trends in Biotechnology, CELL Press 35, 582-585 (2017).
Ariel Fernández: “Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy”. Trends in Cancer, CELL Press 3, 675-677 (2017).
Ariel Fernández: “Deep Learning to Therapeutically Target Unreported Complexes”. Trends in Pharmacological Sciences, CELL Press 40, 551-554 (2019).
Daruma Institute for AI in Pharmaceutical Research
AF Innovation Pharma Consultancy, Q7/P18, San Andrés de la Sierra 8160, Argentina, and
4000 Pemberton Court, Winston-Salem, NC 27106, USA
Phone: 336 354 8315, +54 9291 447 9734
Scientist - Consultant